Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-18T18:07:05.155Z Has data issue: false hasContentIssue false
  • English
  • Français

2178 Drug development core facilitates institutional collaboration and translational science innovation

Published online by Cambridge University Press:  21 November 2018

Gene Morse ,
Igor Puzanov ,
Andrei Gudkov ,
Robin DiFrancesco ,
William Jusko ,
Marc Ernstoff ,
James Mohler ,
Timothy Murphy  and
Robert Bies
Gene Morse
Affiliation:
University at Buffalo, State University of New York
Igor Puzanov
Affiliation:
Roswell Park Cancer Institute
Andrei Gudkov
Affiliation:
Roswell Park Cancer Institute
Robin DiFrancesco
Affiliation:
University at Buffalo, State University of New York
William Jusko
Affiliation:
University at Buffalo, State University of New York
Marc Ernstoff
Affiliation:
Roswell Park Cancer Institute
James Mohler
Affiliation:
Roswell Park Cancer Institute
Timothy Murphy
Affiliation:
University at Buffalo, State University of New York
Robert Bies
Affiliation:
University at Buffalo, State University of New York
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

OBJECTIVES/SPECIFIC AIMS: Drug development is a common research pursuit for basic and clinical scientists that interfaces diagnostic/therapeutic challenges with funding agencies, pharmaceutical industry, regulatory systems, and education. The University at Buffalo Clinical and Translational Science Institute (CTSI) has implemented a Drug Development Core (DDC) with goals that foster team science and collaboration, optimize laboratory use, and networks investigators. Our goals are to foster collaborations within the region and with other CTSAs. METHODS/STUDY POPULATION: The DDC met with 300 potential investigators from 14 departments and several local companies. There were 35 portal requests from 15 departments and 7 companies; 8 were from training programs. For 28 requests, a reviewer provided consultation, while 7 required discussions and review of data. DDC assisted with 15 grant applications (outcomes pending), 10 industry-related new drug development requests and 1 regulatory review. Curriculum reviews noted overlap and gaps. Cross-institute opportunities for M.D.-Ph.D. research mentoring were identified. RESULTS/ANTICIPATED RESULTS: The DDC met with 300 potential investigators from 14 departments and several local companies. There were 35 portal requests from 15 departments and 7 companies; 8 were from training programs. For 28 requests, a reviewer provided consultation, while 7 required discussions and review of data. DDC assisted with 15 grant applications (outcomes pending), 10 industry-related new drug development requests and 1 regulatory review. Curriculum reviews noted overlap and gaps. Cross-institute opportunities for M.D.-Ph.D. research mentoring were identified. DISCUSSION/SIGNIFICANCE OF IMPACT: The CTSI DDC was well received by investigators. The request process fosters collaboration among researchers with similar interests and identifies core laboratory resources that add innovation to ongoing research, funding applications, education, and interinstitutional planning.

Type
Basic/Translational Science/Team Science
Information
Journal of Clinical and Translational Science , Volume 2 , Supplement S1 , June 2018 , pp. 10 - 11
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Association for Clinical and Translational Science 2018